Iterum Therapeutics plc (PNK: ITRMF) Stock Competitors & Peer Comparison

Iterum Therapeutics plc (PNK: ITRMF) plays a significant role within the Healthcare sector. Its performance on the PNK reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ITRMF stands at 2.7M. In comparison, SGMO has a market cap of 30.7M. Regarding current trading prices, ITRMF is priced at $0.05 on the PNK, while SGMO trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ITRMF currently has a P/E ratio of -0.07, whereas SGMO's P/E ratio is -0.20. In terms of profitability, ITRMF's ROE is +4.42%, compared to SGMO's ROE of +66.86%. Regarding short-term risk, ITRMF is less volatile compared to SGMO. This indicates lower risk in terms of short-term price fluctuations for ITRMF.Check SGMO's competition here

Iterum Therapeutics plc (PNK: ITRMF) plays a significant role within the Healthcare sector. Its performance on the PNK reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ITRMF stands at 2.7M. In comparison, ADTX has a market cap of 3.7M. Regarding current trading prices, ITRMF is priced at $0.05 on the PNK, while ADTX trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ITRMF currently has a P/E ratio of -0.07, whereas ADTX's P/E ratio is N/A. In terms of profitability, ITRMF's ROE is +4.42%, compared to ADTX's ROE of +9.26%. Regarding short-term risk, ITRMF is less volatile compared to ADTX. This indicates lower risk in terms of short-term price fluctuations for ITRMF.Check ADTX's competition here

Iterum Therapeutics plc (PNK: ITRMF) plays a significant role within the Healthcare sector. Its performance on the PNK reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ITRMF stands at 2.7M. In comparison, CASIF has a market cap of 2.6M. Regarding current trading prices, ITRMF is priced at $0.05 on the PNK, while CASIF trades at $0.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ITRMF currently has a P/E ratio of -0.07, whereas CASIF's P/E ratio is -0.05. In terms of profitability, ITRMF's ROE is +4.42%, compared to CASIF's ROE of +2.04%. Regarding short-term risk, ITRMF is more volatile compared to CASIF. This indicates higher risk in terms of short-term price fluctuations for ITRMF.Check CASIF's competition here

Iterum Therapeutics plc (PNK: ITRMF) plays a significant role within the Healthcare sector. Its performance on the PNK reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ITRMF stands at 2.7M. In comparison, OCEA has a market cap of 237.3K. Regarding current trading prices, ITRMF is priced at $0.05 on the PNK, while OCEA trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ITRMF currently has a P/E ratio of -0.07, whereas OCEA's P/E ratio is N/A. In terms of profitability, ITRMF's ROE is +4.42%, compared to OCEA's ROE of +0.04%. Regarding short-term risk, ITRMF is less volatile compared to OCEA. This indicates lower risk in terms of short-term price fluctuations for ITRMF.Check OCEA's competition here

Iterum Therapeutics plc (PNK: ITRMF) plays a significant role within the Healthcare sector. Its performance on the PNK reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ITRMF stands at 2.7M. In comparison, AFMDQ has a market cap of 1.6K. Regarding current trading prices, ITRMF is priced at $0.05 on the PNK, while AFMDQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ITRMF currently has a P/E ratio of -0.07, whereas AFMDQ's P/E ratio is N/A. In terms of profitability, ITRMF's ROE is +4.42%, compared to AFMDQ's ROE of -1.01%. Regarding short-term risk, ITRMF is more volatile compared to AFMDQ. This indicates higher risk in terms of short-term price fluctuations for ITRMF.Check AFMDQ's competition here

Iterum Therapeutics plc (PNK: ITRMF) plays a significant role within the Healthcare sector. Its performance on the PNK reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ITRMF stands at 2.7M. In comparison, BIORQ has a market cap of 905. Regarding current trading prices, ITRMF is priced at $0.05 on the PNK, while BIORQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ITRMF currently has a P/E ratio of -0.07, whereas BIORQ's P/E ratio is N/A. In terms of profitability, ITRMF's ROE is +4.42%, compared to BIORQ's ROE of +1.22%. Regarding short-term risk, ITRMF is more volatile compared to BIORQ. This indicates higher risk in terms of short-term price fluctuations for ITRMF.Check BIORQ's competition here